- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Apimeds Pharmaceuticals closes $100 million PIPE financing | 1 | Investing.com | ||
| Mi | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.12. | Apimeds merges with MindWave to combine biotech and digital assets | 1 | Investing.com | ||
| 01.12. | Apimeds Pharmaceuticals US, Inc. and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE | 494 | Business Wire | Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven... ► Artikel lesen | |
| 18.11. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | Apimeds partners with University of Alabama for pharmaceutical innovation | 2 | Investing.com | ||
| APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
| 25.08. | Apimeds kooperiert mit University of Alabama bei Pharma-Innovation | 2 | Investing.com Deutsch | ||
| 19.08. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 16.07. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | Apimeds Pharmaceuticals stärkt Management mit zwei neuen Führungskräften | - | Investing.com Deutsch | ||
| 15.07. | Apimeds Pharmaceuticals adds two key executives to leadership team | 3 | Investing.com | ||
| 16.05. | D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. in connection with its $13.5 Million Initial Public Offering | 567 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in... ► Artikel lesen | |
| 12.05. | Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering | 220 | GlobeNewswire (Europe) | Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| COGENT BIOSCIENCES | 41,290 | +3,12 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| LENZ THERAPEUTICS | 17,500 | -28,60 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ) in South Korea for the Treatment of Presbyopia | SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus... ► Artikel lesen | |
| BIONTECH | 80,95 | -0,98 % | Märkte am Morgen: Nvidia, Netflix, Paramount Skydance, Bayer, HelloFresh, BioNTech, ASML | Die Sitzung der US-Notenbank am Mittwoch ist das beherrschende Thema in dieser Woche. Am deutschen Aktienmarkt zeigte sich der DAX im Vorfeld zurückhaltend, schloss aber immerhin leicht in der Gewinnzone.... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 33,070 | +4,82 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| RECURSION PHARMACEUTICALS | 4,360 | -4,80 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 89,03 | +1,39 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| VOR BIOPHARMA | 12,630 | +3,87 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 71,85 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| STRUCTURE THERAPEUTICS | 67,51 | +0,10 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOVANT | 26,320 | +6,09 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| VERA THERAPEUTICS | 49,750 | +8,11 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ARCUS BIOSCIENCES | 21,775 | -13,42 % | Arcus Biosciences And Gilead Discontinue Phase 3 STAR-221 Study In Cancer Due To Futility | FOSTER CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Friday the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,420 | -0,33 % | Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting | Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Resolution of Anemia... ► Artikel lesen |
Das Unternehmen APIMEDS PHARMACEUTICALS US INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,30 % bei einem Aktienkurs von 2,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APIMEDS PHARMACEUTICALS US INC finden Sie auf Wallstreet Online.